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This study was conducted to develop mucoadhesive buccal tablet of Frusemide. A Mucoadhesive buccal tablet 
of Frusemide were prepared by using wet granulation method using dfferent polymer such as HPMC k 100, 
Carbopol-940 in different ratio. Tablets were analysed by measuring different parameters thickness, hardness 
weight uniformity, drug content uniformity, LOD, sweeling index, invitro dissolution study and solubility. The 
tablets were evaluated for in vitro release in pH 6.8-phosphate buffer for 12 hr in standard dissolution apparatus. 
Mucoadhesion strength was increased with increase in the concentration of carbopol. In order to determine the 
mode of release, the data was subjected to Zero order, first order, Higuchi and Peppas diffusion model. 
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Bioadhesion may be defining as the state in which two materials, at least one of which is biological in nature, 
are held together for extended period by interfacial forces. In the pharmaceutical sciences, when the adhesive 
attachment is to mucous membrane the phenomenon is referred to as mucoadhesion (1). Furosemide is a potent 
loop diuretics chemically designated as 4-chloro-2-(2-furosemideylmethylamino)-5-sulfamoyl-benzoic acid. 
Sparingly soluble in alcohol, freely soluble in dilute alkali solution and insoluble in dilute acid [3]. Furosemide 
is rapidly but incompletely absorbed following oral administration and undergoes first pass metabolism resulting 
in a narrow absorption window, leads to its low bioavailability (43-50 %). The biological half life of Furosemide 
is (1-2 hrs).The physicochemical properties of Furosemide, its low half-life and molecular weight (330.7g/mol) 
make it suitable candidate for administration by buccal route. Hence the present study is aimed to prepare and 
evaluate buccal tablets of Furosemide using various bioadhesive polymers, in order to overcome bioavailability 
related problems, to reduce dose dependent side effects and frequency of administration [4]. Drug can be 
administered by many different routes to produce a systemic pharmacological effect. The most convenient and 
common route of administration is oral probably 90% of the drugs are given by this route [5]. The main problem 
of furosemide for delivery as potential therapeutic agent is their extensive pre-systemic metabolism resulting in 
a narrow absorption window, leads to its low bioavailiability (43-50) [4]. 
2. Materials and methods 
Furosemide (AR No.69170 FRSO,ASI30), and Micro Crystalline Cellulose,Cabopol,HPMCK 100Lactose were 
obtained from Time Pharma Pvt. Ltd. as gift sample.Talc ( B. No.584048 of Nike), Magnesium Stearate (Loba 
Chemie Pvt. Ltd, Mumbai), Sodium Hydroxide pellets (Qualigens fine chemicals, B.No. K11X/2611/1411/08), 
Potassium Dihydrogen Orthophosphate (Qualigens fine chemicals, B.No.- 26735), Disodium hydrogen 
phosphate,PVPK 30 were provided by our college Shree  Medical and Technical College by purchasing from 
local market. Marketed product was purchased from local retail pharmacy. 
2.1 Equipment and instruments 
2.2 Method of Preparation of buccoadhesive tablets 
Wet granulation method was employed to prepare buccal tablets of furosemide using different polymers such as 
HPMC k 100, Carbopol-940  in different ratio. 
2.3 Preparation 
Mucoadhesive matrix tablet each containing 40mg of furosemide were prepared by non‐ aqueous granulation 
method (using isopropyl alcohol). All the ingredients except lubricants were mixed in the order of ascending 
weights and blended for 10 min in an inflated polyethylene pouch and then furosemide was added in this 
mixture then mixed for 2 min for uniform mixing. Granulation was done with binder solution of PVP which was 
previously dissolved in isopropyl alcohol, this damp mass passed through 10 no. Sieve. This was dried in air and 
passed through 16 no. Sieve and lubricants such as magnesium stearate, talc & sweetening agent Manitol were 




mixed and then compressed it with 10‐ station rotary compression machine into 150mg tablet, to a hardness of 
6‐ 10 kg/cm2 using 6.5 mm punch. 
Table No. 2: Equipment and instruments 
 
S. No. Instruments and devices Specifications 
1 UV-Visible spectrophotometer 
Electrolab, Model No: Double beamLT-
2900 
2 Rotary tablet press SHIV (10 station), India 
3 Dissolution test apparatus USP 24 (Type II), Model No : DA-6S 
4 Disintegration test apparatus SHIV, India 
5 Analytical balance (d= 0.01) 
Shinko Denshi Co. Ltd., China Model 
No.: AJ220E 
6 Tablet Hardness Tester Monsanto Hardness Tester, India 
7 Vernier caliper - 
8 Hot air oven SHIV, India 
9 Friability test apparatus SHIV, India 
10 pH meter HANNA instrument 
11 Magnetic stirrer MLH 
12 Sintered glass of grade 2 Borosilicate, India 
13 Glassware Borosilicate, India 
14 Refrigerator LG, Model No.- GC-151SA 
2.4 Calibration Curve 
The stock solution of concentration 500 µg/ml was prepared. Various solution of concentration (2, 4, 6 and  8) 
was prepared from that solution. The data obtained from UV was plotted to obtained plot of absorbance vs. 
concentration (linearity curve). Finally the correlation coefficient of the solution was calculated to validate the 
analytical process [8]. 
3. Evaluation of active Furosemide 
Loss on Drying 
The sample of Furosemide was taken and heated at 105˚C for 3 hours in hot air oven. The initial weight and the 
final weight of the sample of furosemide were determined. The difference in initial weight and final weight was 
obtained which was further processed to calculate loss on drying value of active Furosemide [9].   
Assay 




Dissolve about 600 mg of furosemide, will be accurately weighed, in 50 ml of dimethylformanide to which has 
been added 3 drops of bromothymol blue TS, and which previously has been neutralized with 0.1 N Sodium 
hydroxide. Titrate with 0.1 N sodium hydroxide VS to a blue endpoint [10]. 
Solubility 
Solubility determinations were performed by taking an excess amount of Furosemide in a beaker, in 10 ml of an 
aqueous and 0.1N HCl solution containing various concentrations of PEG 6000. The samples were shaken at 37 
± 0.5 °C for 24 hrs.in a magnetic stirrer. After 24hrs, the samples were filtered. The filtrate was suitably diluted 
and analyzed in spectrophotometer at274 nm using a UV spectrophotometer [11]. 
Evaluation of granules of Furosemide 
All the prepared mucoadhesive tablets will be evaluated for following parameters. 
Bulk density and Tap densities 
Exactly 50 gm of powder blend will be weighed on chemical balance and transferred into a 100 ml measuring 
cylinder. The cylinder will be dropped on a wooden plat form from a height of 2.5 cm three times at 2 seconds 
interval. The volume occupied by the granules will be recorded as the bulk volume. The cylinder will be then 
tapped on the wooden platform until the volume occupied by the powder blend remained constant. This will be 
repeated three times for blend. The data generated will be used in calculating the Carr’s compressibility index 
and Haunser’s ratio [5]. 
              
    
               
 
               
    
             
 
Angle of repose  
50 gm of  powder blend will be placed in  a plugged glass  funnel which had a distance of 10 cm from the 
flat surface. The blend will be  then allowed to flow through the 8mm funnel orifice by removing the cotton 
plug from the funnel orifice. The height of the heap (h) formed as well as the radius of the heap (r) will be noted 
[5]. 





‘θ’ is the angle of repose 




‘h’ is height of pile 
‘r’ is radius of the base of pile  
Carr’s Index 
The compressibility index of the granules was determined by Carr’s index.Carr’s index can be calculated by 
using the following formula [8]. 
             (  
             
                  
)      
Hausners Ratio 
Hausners ratio is the indication of the compressibility of a power. Hausners ratio of the mixed powder was 
calculated by following formula [8]. 
               
   
                
 
Evaluation of furosemide tablets 
Friability  
Friability is the measure of tablet strength. Roche type friabilator will be used for testing the friability using the 
following procedure. Twenty tablets will weighed accurately and placed in the tumbling apparatus that revolves 
at 25 rpm dropping the tablets through a distance of six inches with each revolution. After 4 min, the tablets will 
be weighed and the percentage loss will be determined [12]. 
% loss =( initial weight- Final weight) 
initial weight 
In-Vitro dissolution studies 
Release of drug, from the Furosemide tablet will be determined using USP dissolution apparatus and the 
dissolution rate will be studied using 900 ml of phosphate buffer PH 6.8 [13]. 
Hardness  
Hardness will be measured using Monsanto hardness tester. For each batch three tablets will be tested [7]. 
Swelling index  
* 1oo 




The swelling index of the buccal tablet will be evaluated by using pH 6.8-phosphate buffer. The initial weight of 
the tablet will be determined (w1). The tablets will be placed in pH 6.8 phosphate buffer (25 ml) in a Petri-dish 
will be placed in an incubator at 37 ± 1˚C and tablet will be removed at different time intervals (0.5, 1.0, 2.0, 
3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 h), excess water will be removed using filter paper without pressing and reweighed 
(w2). The swelling index will be calculated using the formula: 
Swelling index = 100 (w2-w1) / w1 [7]. 
Thickness 
Three tablets was selected randomly from each batch and thickness was measured by using vernical calliper [7]. 
 Weight Variation  
Twenty tablets was randomly selected from each batch and individually weighed. The average weight and 
standard deviation of 20 tablets was calculated. The batch was passed the test for weight variation test if not 
more than two of the individual tablet weight deviate from the average weight by more than the percentage 
shown in Table No.3 and none deviate by more than twice the percentage shown [7].  
Table No. 3:  Percentage deviation allowed under weight variation test 
S.N Average wt. of Tablets (mg) Percentage 
1.  130 or less 10 
2.  130-324 7.5 
3.  More than 324 5 
Assay 
 Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.1 g of Frusemide 
and shake with 150 ml of 0.1 M sodium hydroxide for 10 minutes. Add sufficient 0.1 M sodium hydroxide to 
produce 250.0 ml and filter. Dilute 5.0 ml to 200.0 ml with 0.1 M sodium hydroxide and measure the absorbance 
of the resulting solution at the maximum at about 271 nm (2.4.7). Calculate the content of C12H11ClN2O5S 
taking 580 as the specific absorbance at 271 nm [9] 
4. Results 
4.1 Calibration Curve 
  
   
√       
 




Correlation Coefficient was found to be 0.997 









Fig No.2:  Standard calibration curve of furosemide in 0.1 M NaOH 
4.2  Evaluation of active Furosemide 
Loss on Drying 
Loss on drying was found to be 0.375%. 
Assay 
Assay of T1, T2 and T3 and found as 96.001%, 97.41% and 104.234% respectively, average assay = 99.2152%, 
on dried basis it was 98.62%. Where Limit is 98% - 101% on dried basis according to IP. 
4.3 Evaluation of developed formulation 
The powder blend of the formulated product was checked for bulk density,tapped density, angle of repose, 





























Fig No.3: Bulk density of Formulated Products 
 
Fig No.4: Tapped density of Formulated Products 
 











































































Fig No.6: Hausner’s ratio of Formulated Products 
4.4 Evaluation of furosemide tablets 
Physiochemical Properties 
The weight, thickness, hardness, friability of the tablets of furosemide were determined. The hardness was in the 
range of 5 to 10 kg/cm
2
 hardness increases with increasing carbopol porportion in the formulation. Friability 
was in the range of 0.32 to 0.67% less than 1% indicates good mechanical strength to withstand the rigors of 
handling and transportations and thickness was in the range of 4.0 mm to 5.1 mm. Weight of buccal tablets were 
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The results of all the above parameters are listed in table below. 
Table 5 
EVALUATION OF BOTH GRANULES OF FUROSEMIDEBUCCAL TABLETS AND FORMULATED FUROSEMIDE TABLETS 
Formulation Bulk density Tap density Carr's Hausner's Angle of Hardness Friability Thickness Assay Weight 
code (gm/cc) (gm/cc) index% Ratio Repose (Kg/cm3)* (%) (mm)* (% purity) (mg)* 
F1 0.32 0.39 17.15 1.2 26 6.5±0 0.033 4±0 102.2 149.4 
F2 0.31 0.38 17.15 1.23 28 6.9±0.2 0.033 4.14±0.2 92.9 148.7 
F3 
0.32 
 0.4 18.05 1.22 30 6.8±0.2 0.035 5.1±0.5 93.25 146.6 
F4 0.32 0.4 21.46 1.27 25 9.4±0.8 0.033 4.1±0.5 94.9 147.65 
F5 0.33 0.41 20.78 1.26 32 10.1±0.2 0.032 4.36±0.1 92.5 153.6 
F6 0.31 0.38 17.99 1.21 30 9.6±0.8 0.032 4.3±0.1 99.28 155 
F7 0.32 0.38 17.37 1.21 28 9.8±0.4 0.067 4.1±0.1 93.085 148.7 
 
Mp 
 … … … … … 5.02±0.3 0.35 2.5±0.3 91.41 219.95 
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In-Vitro Dissolution Study 
The cumulative percentage drug releases from the different formulations were given in Annex No. 10. The 
dissolution profile of  different batch of formulated tablets was shown in Fig No.7. 
 
 
Fig No.7: Dissolution Profile of Formulated Furosemide Tablets 
 




























































Fig No.9: Dissolution Profile of Formulation 7 
4.5 Evaluation of marketed product 
Physiochemical Properties 
The weight ,hardness, friability of the tablets of market product averages  were found to be as 219.95 mg, 
5.02kg/cm
2
 and 0.350% respectively. 
The assay  was found to be 91.41. The results of all the above parameters are listed in Annex No. 6 and 7 
In-Vitro Dissolution Study of Marketed Furosemide Tablets  
The cumulative percentage drug release from the marketed furosemide tablet is given in Annex No. 11. The 
dissolution profile of furosemide tablet was shown in Figure No.10 
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4.6 Comparision between the formulated products with marketed products 
The cumulative percentage drug release from the marketed  product and formulated product is given in Annex 
No. 11. The dissolution profile of tablets was shown in Figure No.11. 
 
Fig No.11: Dissolution profile of formulated products and marketed products 
The % drug release of the Market product F1, F2, F3, F4, F5, F6, F7 was found to be 




Formulation code   
 Regression  
Coefficient 
values of     
 
Zero order First order Higuchi korsemeyer's 
     F1 -0.43 0.9 0.82 0.9 
F2 -0.34 0.87 0.81 0.88 
F3 0.84 0.81 0.89 0.95 
F4 -1.8 0.92 0.55 0.92 
F5 -1.58 0.95 0.63 0.95 
F6 -2.26 0.9 0.41 0.88 
F7 0.88 0.9 0.84 0.91 
MP -0.62 0.8 0.69 0.83 
4.7 Analysis and Intrepretation 
Model dependent method 
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the above data it was evident that all the formulations displayed mixed order release kinetics (“r values ranging 
from -2.26 to 0.952’’) 
Model independent method 
The similarity factor f2 was calculated by comparing its dissolution profile with marketed product and was 
found to be 17.78, which show quite distinct differences in dissolution profile between them.   
5. Discussion 
Tablets of Furosemide were prepared by wet granulation method using mucoadhesive polymers like carbopol 
940, HPMC K100 in different ratios. According to work plan,the Tablets were evaluated for their apperance, 
thickness, hardness, friability, weight variation, swelling index, in vitro release. The results of granules 
evaluation suggest that all the granules exhibits good flow properties, as angle of repose values were less than 
30. A good packing ability of the granules was indicated by Carr’s index and Hausner ratio. Weight of tablets 
were found to be uniform. The hardness was in the range of 5 to 10 kg/cm3 hardnes increases with increasing 
carbopol porportion in the formulation. Similar result was reported by Bhaskar and his colleagues 2012, which 
showed that the formulated tablet hardness was found to be in the range 5-8 kg/cm3 it was increases by 
increasing the proportion of Carbopol, And the friability was in the range of 0.32 to 0.67% less than 1% similar 
result was represented by Bhaskar and his colleagues 2012, Friability of 0.322 to 0.98 %, indicates good 
mechanical strength to withstand the rigors of handling and transportations and thickness was in the range of 4.0 
mm to 5.1 mm. Weight of buccal tablets were found to be in the range of 138 to 163mg. The swelling index 
carried out for 70 min. These profile indicates the uptake of water into the tablet matrix, producing an increase 
an weight. The swelling state of the polymer (in the formulation) was reported to be crucial for its bioadhesive 
behavior. Adhesion occurs shortly after the begining of swelling but the bond formed between mucosal layer 
and polymer was not very strong. In formulations maximum swelling was seen with the formulation containing 
Carbopol 940. Result indicates that the concentration of Carbopol 940 increases the swelling index increases. 
Similar result was indicated by Bhaskar and his colleagues 2012. In vitro release studies were carried out in USP 
XXIII tablets dissolution test appratus-II employing paddle stirrer at 50 rpm and 900ml of ph 6.8 phosphate 
buffer as dissolution mmedium. The in vitro dissolution data of all the designated formulations were shown in 
above tables and dissolution profiles deplicated in figures 7-11, from dissolution data it was evident that 
designed formulations have displayed in the range of 19.38% to 100.10% drug release in 6 hour. In vitro drug 
release data of all the buccal tablet formulations of furosemide was subjected to goodness of fit test by linear 
regression analysis according to zero order kinetics, First order kinetics, Higuchi’s and peppas equations to 
ascertain mechanism of drug release. The results of linear regression analysis including regression coefficients 
were summarized in above table; from the above data it was evident that all the formulations displayed mixed 
order release kinetics (“r values ranging from -2.26 to 0.952’’) 
6. Conclusion 
From the present study, the following conclusions can be drawn: Mucoadhesive buccal tablets of furosemide 
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can be prepared by wet granulation method using Carbopol 940, HPMC K 100 as mucoadhesive polymers in 
different ratios. In all the tablet formulation, PVP-K30 solution in IPA was used as binder, which showed 
acceptable hardness of prepared tablets. All the prepared tablet formulations were found to be good without 
capping and chipping. As the amount of Carbopol polymer in the tablets increases, the drug release rate 
decreases, whereas HPMC K 100 containing formulation show increase in release rate with increase in 
concentration.  Among the 7 formulations, the formulations F5 and F7 released 100.1% and 98.31% respectively 
in 6 hr. All the designed formulations of furosemide buccal tablets displayed mixed-order release kinetics.  
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